Division of Neurology and Epidemiology, Federal University of Bahia, Salvador-Bahia, Brazil.
Clin Ther. 2012 May;34(5):1049-55. doi: 10.1016/j.clinthera.2012.03.001. Epub 2012 Mar 31.
Levodopa is considered the gold standard therapy for Parkinson's disease (PD). Aspiration pneumonia is the most frequent cause of death among PD patients. Asymptomatic respiratory impairment can be detected even in the initial stages of the disease course; however, there is no conclusive evidence regarding the efficacy of levodopa, the main therapeutic drug for PD, to enhance pulmonary function in these patients.
The aim of this systematic review and meta-analysis was to evaluate the effects of levodopa therapy on respiratory parameters in patients with PD.
After a comprehensive and systematic literature search in the electronic databases MEDLINE, Embase, the Cochrane Library, and Web of Science, all trials referring to levodopa and respiratory function that met the eligibility criteria were included in the analysis. Considered outcomes were forced vital capacity (FVC), forced expiratory volume in 1 second (FEV(1)), the ratio between FEV(1) and FVC (FEV(1)/FVC), and peak expiratory flow (PEF). The fixed effects model was used to assess the weighted mean difference, and heterogeneity between studies was calculated with the I(2) test.
Four clinical trials comprising 73 patients and assessing the effects of levodopa on pulmonary function in patients with PD were included in the analysis. Pooled data showed that levodopa significantly improved FVC (SMD, 0.40; P = 0.02) and PEF (standard mean difference, 0.39; P = 0.03). No significant change was observed with FEV(1) (SMD, 0.34; P = 0.05) or the FEV(1)/FVC ratio (standard mean difference, -0.08; P = 0.66) after levodopa therapy.
The results of this systematic review suggest that levodopa therapy improved FVC and PEF, whereas no changes were observed in FEV(1) and FEV(1)/FVC. These findings may provide some indirect evidence regarding the efficacy of levodopa in restrictive parameters of pulmonary function.
左旋多巴被认为是治疗帕金森病(PD)的金标准疗法。吸入性肺炎是 PD 患者死亡的最常见原因。即使在疾病早期也可以检测到无症状性呼吸功能障碍;然而,对于 PD 主要治疗药物左旋多巴是否能改善这些患者的肺功能,目前尚无确凿证据。
本系统评价和荟萃分析旨在评估左旋多巴治疗对 PD 患者呼吸参数的影响。
通过对 MEDLINE、Embase、Cochrane 图书馆和 Web of Science 电子数据库进行全面系统的文献检索,将符合纳入标准的所有涉及左旋多巴和呼吸功能的试验均纳入分析。考虑的结局指标为用力肺活量(FVC)、1 秒用力呼气量(FEV(1))、FEV(1)与 FVC 的比值(FEV(1)/FVC)和呼气峰流速(PEF)。采用固定效应模型评估加权均数差,并采用 I(2)检验计算研究间的异质性。
纳入了 4 项临床试验,共 73 例患者,评估了左旋多巴对 PD 患者肺功能的影响。汇总数据显示,左旋多巴治疗可显著改善 FVC(SMD,0.40;P = 0.02)和 PEF(标准均数差,0.39;P = 0.03)。左旋多巴治疗后 FEV(1)(SMD,0.34;P = 0.05)或 FEV(1)/FVC 比值(标准均数差,-0.08;P = 0.66)无显著变化。
本系统评价的结果表明,左旋多巴治疗可改善 FVC 和 PEF,但 FEV(1)和 FEV(1)/FVC 无变化。这些发现可能为左旋多巴在肺功能限制性参数方面的疗效提供了一些间接证据。